Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

IPC General

Displaying 1 to 10 of 104 Posts . Displaying 10 of Posts . Page of 11 . Go To Page: . Per Page: . . . View All Sort By: .

New IPC Councilor

Dr. Claus Johansen joins the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world.

Read More

PsoProtect Registry Data Update

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases.

Read More

Arcutis Biotherapeutics, Inc. Announced Findings From the Skin Insights: Uncovering Psoriasis Survey

Arcutis Biotherapeutics, Inc. shared their finding from the Skin Insights: Uncovering Psoriasis Survey.

Read More

Dermavant Announces FDA Approval for VTAMA® (Tapinarof) Cream

Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.

Read More

Bristol Myers Squibb (BMS) Announces New Two-Year Deucravacitinib Data

Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis.

Read More

New Corporate Member

IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!

Read More

Newest IPC Councilors

Three councilors join the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world.

Read More

PsoProtect Registry Data Update

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,525 cases.

Read More

Amgen announces new Otezla (apremilast) data

Amgen presents new data on the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.

Read More

Janssen initiates first-of-its-kind clinical study to bridge critical gaps in care for people of color with moderate to severe plaque psoriasis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color.

Read More

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK